MedTrace Logo

Observational Study on the Use of Akynzeo® in Patients Receiving HEC

NCT03649230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 207

Last updated 2023-08-18

Study results available
· View outcomes & findings →

Summary

This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology patients receiving highly emetogenic chemotherapy (HEC).

Conditions

  • Chemotherapy-Induced Nausea and Vomiting

Interventions

DRUG

300mg netupitant/0.5mg palonosetron hydrochloride

Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)

Sponsors & Collaborators

  • Purdue Pharma, Canada

    lead INDUSTRY

Principal Investigators

  • Jodan Ratz, PhD · Purdue Pharma, Canada

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-03
Primary Completion
2019-12-30
Completion
2020-01-30
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649230 on ClinicalTrials.gov